🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Lumos has received confirmation of Medicare reimbursement coverage from two additional Medicare Administrative Contractors (MACs), retroactive from 1 April 2025. Read the ASX release: bit.ly/LDX-Additional… $LDX #LDX #rapidtest #diagnostics #pointofcare #innovation #healthcare

$LDX | Lumos Diagnostics (ASX:LDX) has released its quarterly report for the period ending 31 March 2025. Read the ASX release: bit.ly/LDX-Quarterly-… $LDX #LDX #Lumos #pointofcare #diagnostics #innovation #healthcare

📍Dallas, Texas | Lumos Diagnostics is a sponsoring exhibitor at the 2025 Urgent Care Convention. Visit us at Booth #817 to learn more about how FebriDx® is changing the landscape for antimicrobial stewardship. $LDX #LDX #Lumos #pointofcare #diagnostics #AMR

$LDX Lumos CEO and MD, Doug Ward, and CFO, Barrie Lambert, this week presented the Company's Q3 FY25 quarterly results. Take a look: youtu.be/G5MEessvE3w?si… #pointofcare #diagnostics #healthcare

$LDX | Check out this Stockhead article outlining how #Lumos is positioning itself in the rapidly growing point-of-care diagnostics sector, and how FebriDx is driving growth for the Company. Take a look: bit.ly/LDX-Stockhead_… #LDX #pointofcare #diagnostics #healthcare

Analyst report | MST Access Senior Analyst Chris Kallos has released an updated report on #Lumos Diagnostics, highlighting our progress with FebriDx® Medicare reimbursement coverage in the United States. Read the full report: bit.ly/LDX-MST-May2025 $LDX #LDX #diagnostics

#Lumos has announced that it has received and shipped a purchase order for FebriDx® from iMedical, Inc. for US$126,000, representing its largest single purchase order since the test's launch. Read the ASX Release: bit.ly/LDX-iMedical $LDX #LDX #diagnostics #healthcare

#Lumos is pleased to be working with WA-based @TeleMedVET to develop a point-of-care diagnostic solution for equine health monitoring. This partnership demonstrates our strategic approach to #diagnostic development to create fit-for-purpose solutions. $LDX bit.ly/LDX-VET

$LDX | This special report in The The Australian details how #Lumos has achieved Medicare reimbursement from five of seven Medicare Administrative Contractors (MACs), representing more than 70% of total US Medicare payment coverage. Read the full article : bit.ly/LDX-Stockhead-…

#Lumos has received confirmation of Medicare reimbursement coverage for FebriDx from a sixth Medicare Administrative Contractors (MACs), CGS Administrators, retroactive from 1 May 2025. Read the ASX release: bit.ly/LDX_Medicare_2… $LDX #LDX #rapidtest #diagnostics #healthcare

#Lumos has announced that the Company has now successfully achieved 61 bacterial positive patients, representing 50% of the target of 120 bacterial positive patient results required for the study. Read the ASX release bit.ly/LDX_CLIA-Recru… $LDX #LDX #rapidtest #diagnostics

Yesterday's news that #Lumos has reached a critical recruitment milestone in our CLIA Waiver study was featured in a special report in The Australian today. Read the full article: bit.ly/LDX_CLIA_TheOz $LDX #LDX #rapidtest #diagnostics #FebriDx #respiratoryhealth #healthcare

FebriDx® will be used as part of the University of Wollongong's OPTIMAS-GP Trial - a major $2.7 million antimicrobial stewardship study funded by the Australian Government's Medical Research Future Fund. Read the ASX release: bit.ly/LDX-UOW$LDX #LDX #Lumos #FebriDx #AMR

$LDX DEAL | #Lumos Diagnostics has signed a transformational US distribution deal with PHASE Scientific for FebriDx® worth up to US$317m over six years. Read today's #ASX release: bit.ly/LDX_Phase_Scie… #innovation #biotech #healthcare #pointofcare

#Lumos CEO Doug Ward spoke with Proactive presenter Fouad Haidar about the company’s exclusive US distribution agreement for FebriDx® with PHASE Scientific International Limited (PHASE Scientific). Take a look: youtu.be/zRlMS7iMlh8?si… $LDX #LDX #pointofcare #rapidtest #ASX #deal

Stockhead TV | In this interview #Lumos CEO Doug Ward discusses the significance of our exclusive distribution agreement with PHASE Scientific, and why they are the ideal partner for growing FebriDx's footprint in the US. Watch it now: vimeo.com/1101100216?p=1 $LDX #LDX #FebriDx

$LDX | Lumos has today announced a binding A$5.0 million secured loan facility with major shareholders, Tenmile and Ryder Capital. Read the ASX release: bit.ly/LDX_Loan_Facil… #LDX #ASX #pointofcare #diagnostics #FebriDx #healthcare #commercialisation

REPLAY | #Lumos held an investor briefing yesterday outlining the transformational US$317 million distribution agreement with PHASE Scientific. If you missed it, here’s the replay: youtu.be/66nm3ofOAm4 $LDX #LDX #pointofcare #diagnostics #FebriDx #healthcare #commercialisation

29-31 July | We’re heading to #ADLM2025 in Chicago next week. Visit @Lumos_Dx at Booth 3651 to see our reader platforms in action and meet the team behind FebriDx® and our full-service POC diagnostic capabilities. LDX #LDX #Lumos #ADLM2025 #pointofcare #diagnostics #rapidtest

We’re live at #ADLM2025 in Chicago! Visit @Lumos_Dx at Booth 3651 connect with our team and learn more about FebriDx® and our end-to-end point-of-care diagnostic capabilities. $LDX #LDX #Lumos #pointofcare #diagnostics #rapidtest #medtech #FebriDx #healthcare #innovation